Site icon pharmaceutical daily

Sanofi’s 2016 income slightly down

A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann/File Photo

A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann/File Photo

Sanofi has reported net income of €1,6 billion for Q4 2016 which is 6% down compared to the same period last year. The full year income was €7.3 billion, 0.9% down from the last year.

Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
“2016 was a busy year for Sanofi as we progressed on our 2020 strategic roadmap. We successfully closed the Boehringer Ingelheim asset swap, lifting us into a leadership position in Consumer Healthcare. Our streamlined organization started to deliver and supported a stronger financial performance than initially anticipated. At the same time, we completed the filing of our breakthrough innovation Dupixent for the first indication, atopic dermatitis, in the U.S and Europe. Separately, we recently advanced five new molecules into registrational studies.”

The company said that it expects 2017 Business EPS to be stable at constant exchange rates, barring unforeseen major adverse events, consistent with its previously announced Strategic Roadmap guidance for the 2016-17 period.

Exit mobile version